The Effect of Subcutaneous Teriparatide Treatment on Mobility, Back Pain, and Patient Satisfaction in Patients with Vertebral Osteoporotic Fractures: A Cross-Sectional Study with 36-Month Follow-up

被引:0
|
作者
Yilmaz, Ramazan [1 ]
Bagcaci, Sinan [2 ]
机构
[1] Univ Hlth Sci Turkey, Konya Beyhekim Training & Res Hosp, Clin Phys Med & Rehabil, Konya, Turkiye
[2] Konya Medicana Int Hosp, Clin Phys Med & Rehabil, Konya, Turkiye
来源
关键词
Fractures; osteoporosis; teriparatide; back pain; mobility; patient satisfaction; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; MULTICENTER; PREFERENCES; EFFICACY; THERAPY;
D O I
10.4274/haseki.galenos.2023.9388
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: Although the effectiveness of teriparatide on bone mineral density (BMD), fracture risk, and back pain in severe osteoporosis is known, no comprehensive study has been conducted in the Turkish population regarding its impact on mobility and patient satisfaction. This study aimed to evaluate the effectiveness of teriparatide treatment on mobility, back pain, and patient satisfaction in patients with osteoporotic vertebral fractures, as well as its side effects in midterm follow-up. Methods: The study was designed as a retrospective, cross-sectional study. Between February 2018 and April 2023, 50 consecutive patients (mean age 69.9 +/- 9.0 years; range, 53 to 94 years) who were diagnosed with vertebral fractures due to severe osteoporosis and had received 20 mu g/day subcutaneous teriparatide (median, 18 months) were included in the study. The patients were evaluated using BMD measurements, blood tests, radiological imaging, a visual pain score (VAS-pain), mobility assessments [Functional Ambulation Classification (FAC)], and patient satisfaction levels at baseline, 6th, and 18th months. Results: At 6 and 18 months, a significant decrease in VAS-pain and a significant increase in BMD and FAC were observed (p<0.001 for all values). The improvement observed at 6 months continued to increase until the 18th month. 96% of the patients reported being satisfied or very satisfied with the treatment. The treatment of three patients (6%) was discontinued because of side effects in the 15th month of treatment. After the completion of teriparatide treatment, two patients developed clinical vertebral fractures during follow-up. No life-threatening side effects or laboratory abnormalities were observed in any patient. Conclusion: Teriparatide treatment in severe osteoporotic vertebral fractures with back pain has shown a dramatic reduction in pain and significant improvement in ambulation levels, providing high patient satisfaction with reasonable side effects.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 33 条
  • [31] Follow-up of practiced treatment regimens and health conditions of patients following recovery from COVID-19 residing in Dhaka City: a survey-based, descriptive, cross-sectional study
    Khan, Tahsin Shahrin
    Shirin, Tahmina
    Alam, Ahmed Nawsher
    Shakhider, Mohammad Abdul Hannan
    Haque, Fahim
    IJID REGIONS, 2022, 3 : 68 - 75
  • [32] Patient-reported outcomes of 7133 distal femoral, patellar, and proximal tibial fracture patients: A national cross-sectional study with one-, three-, and five-year follow-up
    Vestergaard, Veronique
    Schroder, Henrik Morville
    Hare, Kristoffer Borbjerg
    Toquer, Peter
    Troelsen, Anders
    Pedersen, Alma Becic
    KNEE, 2020, 27 (05): : 1310 - 1324
  • [33] Long-Term Effect of Peripheral Nerve Field Stimulation as Add-On Therapy to Spinal Cord Stimulation to Treat Low Back Pain in Failed Back Surgery Syndrome Patients: A 12-Month Follow-Up of a Randomized Controlled Study
    van Gorp, Eric-Jan J. A. A.
    Teernstra, Onno
    Aukes, Hans J.
    Hamm-Faber, Tanja
    Burger, Katja
    Kallewaard, Jan Willem
    Spincemaille, Geert
    Schapendonk, Johannes W. L. C.
    Vonhogen, Leon
    Bronkhorst, Ewald
    Vissers, Kris C. P.
    NEUROMODULATION, 2019, 22 (08): : 970 - 977